EDIT vs RGNX: stock comparison and AI forecast
Editas Medicine, Inc. (EDIT) and Regenxbio Inc. (RGNX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
EDIT Editas Medicine, Inc.
- Market Cap
- $395M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
RGNX Regenxbio Inc.
- Price
- $7.16 -23.7% · 6M
- Market Cap
- $473M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- RGNX is 1.2 times larger than EDIT by market capitalization ($473M against $395M).
- RGNX carries 4.39 times debt per unit of equity, against 1.25 times for EDIT.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | EDIT | RGNX |
|---|---|---|
| Market Cap | $395M | $473M |
| P/B Ratio | 3.75x | 6.59x |
| EPS | $-1.32 | $-3.67 |
| Book Value/Share | $0.69 | $1.09 |
| Revenue/Share | $0.29 | $2.55 |
| FCF/Share | $-0.78 | $-3.78 |
Profitability & Margins
| Metric | EDIT | RGNX |
|---|---|---|
| ROE | – | -273.7% |
| ROA | – | -50.8% |
| ROIC | -44.9% | -54.0% |
| Operating Margin | -171.7% | -97.7% |
| Net Margin | – | -116.9% |
| EBT Margin | -171.7% | -117.1% |
Financial Health
| Metric | EDIT | RGNX |
|---|---|---|
| Current Ratio | 3.19x | 2.86x |
| D/E Ratio | 1.25x | 4.39x |
| Financial Leverage | 2.25x | 5.39x |
| Interest Coverage | -17.5x | -124.8x |
| Working Capital | $150M | $154M |
Cash Flow
| Metric | EDIT | RGNX |
|---|---|---|
| Operating Cash Flow | -$120M | -$247M |
| Free Cash Flow | -$121M | -$250M |
| Capital Spending | -$690K | -$3M |
| FCF/Sales | -272.9% | -148.5% |
| CapEx/Sales | 1.6% | 1.8% |
Operational Efficiency
| Metric | EDIT | RGNX |
|---|---|---|
| Asset Turnover | 0.19x | 0.43x |
| Receivables Turnover | 16.2x | 1.6x |
| Fixed Assets Turnover | 17.2x | 1.7x |
| Days Sales Outstanding | 23 days | 232 days |
Income Statement
| Metric | EDIT | RGNX |
|---|---|---|
| Total Revenue | $44M | $168M |
| Operating Income | -$76M | -$164M |
| Net Income | – | -$196M |
| R&D Expense | $85M | $229M |
Dividend & Shareholder Information
| Metric | EDIT | RGNX |
|---|---|---|
| Shares Outstanding | 154M | 66M |
EDIT vs RGNX: stock comparison and AI forecast
Which is bigger, EDIT or RGNX?
RGNX is 1.2 times larger than EDIT by market capitalization ($473M against $395M).
Which one does Intratio's AI model rank higher, EDIT or RGNX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.